Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay ...